Experimental HCV Drugs
Experimental HCV Drugs
Simeprevir + Sofosbuvir Works Well for Patients with Advanced Fibrosis
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 11 September 2013 00:00
- Written by Medivir
Nearly all genotype 1 chronic hepatitis C patients achieved early sustained response 4 weeks after finishing a 12-week course of a once-daily interferon-free regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977), with or without ribavirin, according to interim data from the Phase 2 COSMOS trial.
Sofosbuvir + Ribavirin Dual Regimen Cures HCV in Difficult-to-Treat Hepatitis C Patients
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 27 August 2013 00:00
- Written by Liz Highleyman
Nearly two-thirds of genotype 1 chronic hepatitis C patients treated with a 2-drug interferon-free regimen of sofosbuvir plus ribavirin for 24 weeks achieved sustained viral suppression despite having characteristics associated with poor treatment response, researchers reported in the August 28, 2013, Journal of the American Medical Association.
FDA Puts Partial Hold on HCV Drug VX-135 Due to Liver Toxicity at Higher Doses
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 01 August 2013 00:00
- Written by Vertex Pharmaceuticals
The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the experimental HCV polymerase inhibitor VX-135, Vertex Pharmaceuticals announced last week. Testing of the 200 mg dose was suspended in a Phase 2 trial after some patients taking a higher dose developed signs of liver toxicity; testing of the 100 mg dose, however, is continuing.
Faldaprevir + Deleobuvir All-oral Regimen Works Well Against Genotype 1b HCV
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 21 August 2013 00:00
- Written by Liz Highleyman
An interferon-free combination of the direct-acting antivirals faldaprevir and deleobuvir with ribavirin cured hepatitis C in a majority of patients treated for 12 to 40 weeks, but outcomes were significantly better for people with HCV genotype 1b, researchers reported in the August 15, 2013, New England Journal of Medicine.
HCV Protease Inhibitor Sovaprevir Placed on Hold Due to Interaction with HIV Drug
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 19 July 2013 00:00
- Written by Achillion Pharmaceuticals
In early July the U.S. Food and Drug Administration put a clinical hold on Achillion's investigational hepatitis C virus (HCV) protease inhibitor sovaprevir (formerly ACH-1625) due to unexpected liver enzyme elevations observed in healthy volunteers taking sovaprevir with the HIV protease inhibitor atazanavir (Reyataz) in an early drug-drug interaction study.
Web Design and Development by